Skip to content
value.today

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is listed today as Perspective Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Perspective Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$87 MPrivate placement after listing$50 to $250 million

Perspective Therapeutics, Inc.: Private sale, Mar 2024

Investors in this round

9 investors had bought by the notice of Mar 18, 2024: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$87 M of $87 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$5,113,455
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Johan (Thijs) Spoor · Executive Officer, Director
  • Jonathan Hunt · Executive Officer
  • Mark Austin · Executive Officer
  • Markus Puhlmann · Executive Officer
  • Frank Morich · Director
  • Heidi Henson · Director
  • Lori Woods · Director
  • Robert Williamson III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeSci Capital, LLC (CRD 168404) · broker-dealer LifeSci Capital, LLC (CRD 168404) · New York, New YorkSold in CA, CT, MA, NY, and outside the US
  • Oppenheimer & Co. Inc. (CRD 249) · broker-dealer Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in CA, NY, and outside the US
  • B. Riley Securities, Inc. (CRD 25027) · broker-dealer B. Riley Securities, Inc. (CRD 25027) · Los Angeles, CaliforniaSold in CA
  • JonesTrading Institutional Services LLC (CRD 6888) · broker-dealer JonesTrading Institutional Services LLC (CRD 6888) · New York, New YorkSold in NY, and outside the US

Remarks in the notice

  • On the amounts: “Based on 92,009,981 shares of common stock at $0.95 per share.”

Signed by Johan (Thijs) Spoor, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 18, 2024. Read the notice at the SEC.

equitySEC
Jan 2024$21 MPrivate placement after listing$10 to $50 million

Perspective Therapeutics, Inc.: Private sale, Jan 2024

Investors in this round

1 investor had bought by the notice of Jan 22, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
$20,846,671
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Johan (Thijs) Spoor · Executive Officer, Director
  • Jonathan Hunt · Executive Officer
  • Mark Austin · Executive Officer
  • Markus Puhlmann · Executive Officer
  • Frank Morich · Director
  • Heidi Henson · Director
  • Lori Woods · Director
  • Robert Williamson III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Based on 56,342,355 shares of common stock at $0.37 per share.”

Signed by Johan (Thijs) Spoor, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 22, 2024. Read the notice at the SEC.

equitySEC
Feb 2023$55 MPrivate placement after listing$50 to $250 million

Perspective Therapeutics, Inc.: Private sale, Feb 2023

Investors in this round

54 investors had bought by the notice of Feb 21, 2023: 54 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$55 M of $55 M offered
Smallest investment taken
$28,477
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jennifer Streeter · Executive Officer
  • Johan (Thijs) Spoor · Executive Officer, Director
  • Jonathan Hunt · Executive Officer
  • Mark Austin · Executive Officer
  • Markus Puhlmann · Executive Officer
  • Frank Morich · Director
  • Lori Woods · Director
  • Michael McCormick · Director
  • Robert Williamson III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Closing price of $0.40 utilized on merger closing date of February 3, 2023”

Signed by Johan (Thijs) Spoor, Ceo. Source: SEC Form D, newest notice filed Feb 21, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Perspective Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2024

That is all the official record says: Perspective Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Perspective Therapeutics, Inc. are on record.

Investors#

No investor of Perspective Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Perspective Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Perspective Therapeutics, Inc.
NameRoleNamed in
Johan (Thijs) SpoorExecutive officerMar 2024
Jonathan HuntExecutive officerMar 2024
Mark AustinExecutive officerMar 2024
Markus PuhlmannExecutive officerMar 2024
Jennifer StreeterExecutive officerFeb 2023
Frank MorichDirectorMar 2024
Heidi HensonDirectorMar 2024
Johan (Thijs) SpoorDirectorMar 2024
Lori WoodsDirectorMar 2024
Robert Williamson IIIDirectorMar 2024
Michael McCormickDirectorFeb 2023

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.